Cantor Fitzgerald Predicts Higher Earnings for NeuroPace

NeuroPace, Inc. (NASDAQ:NPCE) – Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of NeuroPace in a report issued on Wednesday, March 5th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.54) for the year, up from their previous forecast of ($0.80). Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

Several other research firms have also recently issued reports on NPCE. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. UBS Group assumed coverage on shares of NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Wells Fargo & Company raised their price target on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.20.

NeuroPace Price Performance

NPCE opened at $11.18 on Friday. The company’s 50 day simple moving average is $12.72 and its 200 day simple moving average is $9.77. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. NeuroPace has a 1 year low of $5.45 and a 1 year high of $15.77. The stock has a market capitalization of $333.70 million, a PE ratio of -11.18 and a beta of 2.06.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.47 million for the quarter, compared to analysts’ expectations of $21.14 million.

Institutional Trading of NeuroPace

Hedge funds have recently made changes to their positions in the company. KCK LTD. purchased a new stake in shares of NeuroPace during the fourth quarter valued at approximately $58,981,000. Barclays PLC raised its stake in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares during the period. State Street Corp raised its stake in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the period. Geode Capital Management LLC raised its stake in shares of NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after purchasing an additional 25,330 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after purchasing an additional 6,181 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Activity at NeuroPace

In related news, insider Martha Morrell sold 78,334 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total value of $1,074,742.48. Following the transaction, the insider now owns 81,993 shares in the company, valued at approximately $1,124,943.96. This trade represents a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,352,479 shares of company stock worth $50,670,217. Company insiders own 22.20% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.